Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drug

German pharmaceutical company Boehringer Ingelheim has reported positive outcomes from the first cohort of Beamion LUNG-1, a two-part trial analysing zongertinib for treating non-small cell lung cancer (NSCLC).